Inversago Pharma to Present Data from Phase 1b Trial of INV-202, a Peripheral CB1r Blocker for Metabolic Syndrome, at the 83rd American Diabetes Association Scientific Sessions
Tags:
Phase 1
Diabetes
MONTREAL, Québec--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor blockers to address complications associated with metabolic and fibrotic diseases, today announced that it will present data from the Phase 1b trial for INV-202, at the 83rd American Diabetes Association Scientific Sessions taking place on June 23-26, 2023, in San Diego, California. INV-202 is a potential first-in-class, peripheral CB1r blocker, being developed to treat metabolic disorders and associated complications.
Abstract: Effects of CB1 Antagonist INV-202 in Patients with Metabolic Syndrome—A Randomized, Placebo-Controlled, Double-Blind Phase 1B Study
Presenter: Glenn D. Crater, MD, FCCP, Chief Medical Officer, Inversago Pharma
Poster Session 02-B (431-P): “Complications—Kidney—Clinical and Translational Research”
Author Present Date and Time: Monday, June 26, 2023, 11:30am-12:30pm (PT)
“We look forward to presenting Phase 1b clinical data demonstrating the broad metabolic effects, including weight loss, we saw with Inversago’s INV-202, a peripherally acting CB1r blocker,” said Glenn D. Crater, MD, FCCP, Chief Medical Officer of Inversago Pharma. “We are committed to advancing our innovative pipeline of peripherally acting CB1r blockers to improve the lives of patients with metabolic diseases.”
About INV-202
INV-202 is a small molecule CB1r blocker being developed for the potential treatment of a range of cardiometabolic conditions, including diabetic kidney disease. It is specifically designed to preferentially block CB1 receptors in peripheral tissues such as the kidneys, gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs. The therapeutic effects of peripheral CB1r blockade in a range of cardiometabolic and fibrotic diseases are well-documented, paving the way for potential treatment of a large number of patients with current unmet needs. INV-202 is being evaluated in a Phase 2 study for patients with diabetic kidney disease with results expected in mid 2024.
About Inversago
Based in Montreal Canada, Inversago Pharma, is a privately owned, clinical stage company, and leader in the development of peripherally acting CB1r blocker therapies designed to help patients with complications associated with metabolic and fibrotic diseases. Inversago aims to provide new treatment options that improve the lives of patients affected by diabetic kidney disease (DKD), including diabetic nephropathy (DN), type 1 and type 2 diabetes (T1D / T2D), non-alcoholic steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications like progressive fibrosis-interstitial lung disease (PF-ILD), including idiopathic pulmonary fibrosis (IPF) and other conditions. For more information, visit www.inversago.com.
Contacts
Glenn S. Vraniak Chief Financial Officer Inversago Pharma Inc. info@inversago.com
Media and Investors Argot Partners inversago@argotpartners.com
Glenn S. Vraniak Chief Financial Officer Inversago Pharma Inc. info@inversago.com
Media and Investors Argot Partners inversago@argotpartners.com
